ArticleImmunity2023
Tissue-specific abundance of interferon-gamma drives regulatory T cells to restrain DC1-mediated priming of cytotoxic T cells against lung cancer.
Open access · greenAbstract read
In one paragraph
Article in Immunity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 104 papers.
0numbers the graph read from it
0cells of the map it votes in
104citing papers in PubMed
22.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
104 citing papers in PubMed, 138 citations in OpenAlex.
- Mobilizing antigen-presenting mast cells in anti-PD-1-refractory triple-negative breast cancer: a phase 2 trial.Nature medicine · 2025Trial
- Tumor-Regional Immune Microenvironment: A Critical Factor in the Design of Radiotherapy-Immunotherapy Combination Trials.International journal of cancer · 2026Review
- Article
- Fc-optimized GITR antibody enhances a CD4 T cell-dendritic cell crosstalk to promote antitumor immunity.Nature cancer · 2026Article
- A novel CAF population coordinates hyper-suppressive regulatory T cell recruitment and localization in lung cancer.Nature immunology · 2026Article
- Clonal sharing and plasticity of follicular CD4 + T cells across lymph nodes and tumors in non-small cell lung cancer.Nature communications · 2026Article
- Intratumoral Regulatory T-cell Ablation Mediates Tumor Control Systemically without Autoimmunity.Cancer research · 2026Article
- Targeting regulatory T cells in the prostate cancer microenvironment: From mechanisms to therapeutics (Review).Molecular medicine reports · 2026Review
- Dendritic cell diversity and dysfunction in cancer: implications for immunotherapy and therapeutic targeting.Acta pharmacologica Sinica · 2026Review
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- A Self-Immunoregulatory Nanosensitizer for Sonodynamic Cancer Therapy.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- BTLA and PD-1 combined with radiotherapy for enhancing antitumor immune response in lung cancer via the regulation of memory B cells to promote T-cell infiltration.Translational lung cancer research · 2026Article
- The Treg-cell death axis in lung cancer: implications for immune evasion and novel therapeutic strategies.Molecular cancer · 2026Review
- Multiomics immune profiling of a patient-relevant orthotopic lung cancer model using SEPARATE-Seq.Nature communications · 2026Article
- Targeting immunosenescence in lung diseases: mechanistic insights and clinical interventions.BMC medicine · 2026Review
- CD8Cancer cell international · 2026Review
- Lytic IFNγ is stored in cytotoxic granules and coreleased with granzyme B to mediate cytotoxic T lymphocyte killing.Cellular & molecular immunology · 2026Article
- Hidden immune memory niches in inflammatory skin diseases.bioRxiv : the preprint server for biology · 2026Article
- Lymph node colonization induces tissue remodeling via immunosuppressive fibroblast-myeloid cell niches supporting metastatic tolerance.Cancer cell · 2026Article
- Treg cells retain stable lineage commitment during pregnancy in mice after late gestation inflammatory challenge.Immunology and cell biology · 2026Article
44 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
13 authors at 3 institutions in 1 country.
Maria ZagorulyaKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA; Department of Biology, MIT, Cambridge, MA 02139, USA.
Leon YimKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA.
Duncan M MorganKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA; Department of Chemical Engineering, MIT, Cambridge, MA 02139, USA.
Austin EdwardsBiological Imaging Development CoLab, UCSF, San Francisco, CA 94143, USA.
Elen Torres-MejiaKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA.
Noor MominKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA; Department of Biological Engineering, MIT, Cambridge, MA 02139, USA.
Chloe V McCreeryKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA; Department of Biological Engineering, MIT, Cambridge, MA 02139, USA.
Izabella L ZamoraKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA; Department of Electrical Engineering and Computer Science, MIT, Cambridge, MA 02139, USA.
Brendan L HortonKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA.
James G FoxDepartment of Biological Engineering, MIT, Cambridge, MA 02139, USA; Division of Comparative Medicine, MIT, Cambridge, MA 02139, USA.
K Dane WittrupKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA; Department of Chemical Engineering, MIT, Cambridge, MA 02139, USA; Department of Biological Engineering, MIT, Cambridge, MA 02139, USA.
J Christopher LoveKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA; Department of Chemical Engineering, MIT, Cambridge, MA 02139, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA.
Stefani SprangerKoch Institute for Integrative Cancer Research, MIT, Cambridge, MA 02139, USA; Department of Biology, MIT, Cambridge, MA 02139, USA; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA. Electronic address: spranger@mit.edu.
IIT@MIT · USAllen Institute · USRagon Institute of MGH, MIT and Harvard · US
Funding
Understanding the induction of T cell dysfunction in the context of lung cancerR37CA273819 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Stefani Spranger · 2023 to 2026
$1.9MNCI NIH HHS R37 CA273819
Abstract
Local environmental factors influence CD8
Indexed as
Lung NeoplasmsT-Lymphocytes, RegulatoryCD8-Positive T-LymphocytesHumansInterferon-gammaT-Lymphocytes, CytotoxicIFNG protein, humanInterferon-gammaanti-tumor immunitycross-presenting dendritic cellscytotoxic T cellsinterferon-gammanon-small cell lung cancerregulatory T cellsT cell dysfunctionT cell primingTh1-like effector regulatory T cellstissue-specific immunity
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.